287
Participants
Start Date
August 6, 2013
Primary Completion Date
November 19, 2015
Study Completion Date
September 6, 2018
Docetaxel
Participants received starting dose of 75 mg/m\^2 every three week (q3w) until disease progression, unacceptable toxicity or death. Dose modifications were according to the locally approved label. Participants randomized to receive docetaxel had to be premedicated with corticosteroids according to local practice.
Atezolizumab
Participants received atezolizumab of 1200 mg (equivalent to an average body weight-based dose of 15 milligram per kilogram \[mg/kg\]) which was administered by IV infusion q3w on Day 1 of each 21 day cycle. Participants were allowed to continue treatment beyond progression per response evaluation criteria in solid tumors (RECIST) v1.1 if they were experiencing clinical benefit per investigator, did not have a decline in performance status, did not have signs or symptoms of unequivocal progression, did not have tumor progression at critical sites, and signed an informed consent signature page acknowledging deferment any standard treatment options that may exist in favor of continuing atezolizumab.
UZ Leuven Gasthuisberg, Leuven
Chr de La Citadelle, Liège
Chulalongkorn Hospital; Medical Oncology, Bangkok
Rajavithi Hospital; Division of Medical Oncology, Bangkok
Faculty of Med. Siriraj Hosp.; Med.-Div. of Med. Oncology, Bangkok
New York Oncology Hematology, P.C., Albany
Broome Oncology - Binghamton, Binghamton
Irccs Ospedale San Raffaele;Oncologia Medica, Milan
Centre Hospitalier de Saint Brieuc - Hôpital Yves Le Foll; Pneumologie, Saint-Brieuc
Virginia Cancer Specialists, PC, Fairfax
Virginia Oncology Associates, Norfolk
Blue Ridge Cancer Care, Roanoke
Hospital Ramon y Cajal; Servicio de Oncologia, Madrid
Hospital Universitario 12 de Octubre; Servicio de Oncologia, Madrid
Hospital La Paz, Madrid
Georgia Cancer Specialists, Atlanta
Hopital Larrey; Pneumologie, Toulouse
Istanbul Uni Cerrahpasa Medical Faculty Hospital; Medical Oncology, Istanbul
Fachklinik für Lungenerkrankungen, Immenhausen
Ocala Oncology Center, Ocala
Center for Biomedical Research LLC, Knoxville
Hôpital Nord Michallon; Pneumologie, La Tronche
Karmanos Cancer Institute.., Detroit
Hospital Universitario Miguel Servet; Servicio Oncologia, Zaragoza
Centre D'Oncologie de Gentilly; Oncology, Nancy
Billings Clinic; Research Center, Billings
Ingalls Memorial Hospital, Harvey
Illinois Cancer Care, Peoria
Hopital Gabriel Montpied; Service de Pneumologie, Clermont-Ferrand
Genesis Cancer Center, Hot Springs
Texas Oncology, P.A. - Fort Worth, Fort Worth
Texas Oncology - South Austin, Austin
Rocky Mountain Cancer Centers - Colorado Springs (Circle), Lone Tree
Asklepios-Fachkliniken Muenchen-Gauting; Onkologie, Gauting
Citta Ospedaliera; Divisione Oncologia Medica, Avellino
Arizona Oncology Associates, PC - HOPE, Tucson
Comprehensive Cancer Centers of Nevada - Eastern Avenue, Las Vegas
Innovative Clinical Research Institute, Whittier
Kaiser Permanente - San Marcos, San Marcos
Loma Linda University Medical Center, Loma Linda
Universitätsklinikum Regensburg; Klinik und Poliklinik für Innere Medizin II, Pneumologie, Regensburg
Kaiser Permanente - Vallejo, Vallejo
Northwest Cancer Specialists - Vancouver, Vancouver
Wenatchee Valley Hospital & Clinics, Wenatchee
Providence St. Mary Regional Cancer Center, Walla Walla
New England Cancer Specialists, Scarborough
The Valley Hospital, Paramus
Willamette Valley Cancer Ctr - 520 Country Club, Eugene
Rhode Island Hospital, Providence
Cite de La Sante de Laval; Hemato-Oncologie, Laval
McGill University; Sir Mortimer B Davis Jewish General Hospital; Oncology, Montreal
Krankenhaus Martha-Maria Halle-Doelau gGmbH; Klinik fuer Innere Medizin II, Halle
Uniwersyteckie Centrum Kliniczne, Klinika Onkologii i Radioterapii, Gdansk
Woj.Wielospecjalistyczne Centrum Onkologii i Traumatologii; Oddz.Hematologii Pododz.Chemioterapii, Lodz
Mazowieckie Centrum Leczenia Chorob Pluc I Gruzlicy; Oddzial Iii, Otwock
Centrum Onkologii - Instytut im. Marii Skłodowskiej-Curie Klinika Nowotworów Piersi i Chirurgii, Warsaw
National Cancer Center; Medical Oncology, Gyeonggi-do
Severance Hospital, Yonsei University Health System, Seoul
Samsung Medical Centre; Division of Hematology/Oncology, Seoul
Universitetssjukhuset Linköping; Lungmedicinkliniken, Linköping
Akdeniz University Medical Faculty; Medical Oncology Department, Antalya
Royal Free Hospital; Dept of Oncology, London
Guys and St Thomas NHS Foundation Trust, Guys Hospital, London
Charing Cross Hospital; Medical Oncology., London
Christie Hospital Nhs Trust; Medical Oncology, Manchester
Hoffmann-La Roche
INDUSTRY